Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1996-11-5
pubmed:abstractText
After administration of doses ranging from 0.025 to 0.25 mg/kg, the neuromuscular blocking effect of cisatracurium was assessed in 119 adult surgical patients receiving N2O-opioid-midazolam-thiopental anesthesia. The calculated 95% effective dose (ED95) for inhibition of adductor pollicis twitch evoked at 0.1 Hz was 0.053 mg/kg. With 0.10 mg/kg injected over 5-10 and 20-30 s, median onset times (range) were 5.8 (3.0-7.7) and 4.8 (1.2-10.2) min, respectively, and median times to 5% and 95% recovery (range) were 27 (19-46) and 48 (25-68) min, respectively. For doses of 0.10, 0.20, and 0.25 mg/kg, median 5%-95% and 25%-75% recovery indexes ranged from 48 to 90 min and 8 to 9 min, respectively. After administration of neostigmine (0.06 mg/kg) at 10%-15% or 16%-30% recovery, the median times to 95% recovery (range) were 6 (2-22) and 4 (2-5) min, respectively. There were no changes in heart rate, blood pressure, or plasma histamine concentrations during the first 5 min after administration of cisatracurium at doses up to 5 x ED95 injected over 5-10 s. No cutaneous flushing or bronchospasm was noted. In summary, cisatracurium is a potent neuromuscular blocking drug with an intermediate duration of action, characterized by excellent cardiovascular stability, with no apparent histamine release.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0003-2999
pubmed:author
pubmed:issnType
Print
pubmed:volume
83
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
823-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:8831329-Adolescent, pubmed-meshheading:8831329-Adult, pubmed-meshheading:8831329-Aged, pubmed-meshheading:8831329-Anesthesia, General, pubmed-meshheading:8831329-Anesthesia Recovery Period, pubmed-meshheading:8831329-Anesthetics, Inhalation, pubmed-meshheading:8831329-Anesthetics, Intravenous, pubmed-meshheading:8831329-Atracurium, pubmed-meshheading:8831329-Dose-Response Relationship, Drug, pubmed-meshheading:8831329-Electric Stimulation, pubmed-meshheading:8831329-Female, pubmed-meshheading:8831329-Histamine Release, pubmed-meshheading:8831329-Humans, pubmed-meshheading:8831329-Isomerism, pubmed-meshheading:8831329-Male, pubmed-meshheading:8831329-Midazolam, pubmed-meshheading:8831329-Middle Aged, pubmed-meshheading:8831329-Muscle, Skeletal, pubmed-meshheading:8831329-Muscle Contraction, pubmed-meshheading:8831329-Narcotic Antagonists, pubmed-meshheading:8831329-Narcotics, pubmed-meshheading:8831329-Neostigmine, pubmed-meshheading:8831329-Neuromuscular Nondepolarizing Agents, pubmed-meshheading:8831329-Nitrous Oxide, pubmed-meshheading:8831329-Oxygen, pubmed-meshheading:8831329-Safety, pubmed-meshheading:8831329-Surgical Procedures, Operative, pubmed-meshheading:8831329-Thiopental
pubmed:year
1996
pubmed:articleTitle
Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opioid anesthesia.
pubmed:affiliation
Department of Anesthesiology, Hôtel-Dieu, Centre Hospitalier et Universitaire de Nantes, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't